Disposition of the Highly Fat Distributed Compound 1-(4-Methoxyphenyl)-4-(2,2,4,6,7-Pentamethyl -2,3-Dihydro-1-Benzofuran-5-yl)Piperazine (TAK-357) in Rats and Dogs

Abstract

The non-clinical pharmacokinetics (PK) of TAK-357, a highly lipophilic (clogP>6) potential agent for the amelioration of Alzheimer’s disease, was investigated in rats and dogs. A long half-life (t_1/2) in plasma was observed in animals and a low total body clearance with high distribution volume was consistent with the long t_1/2. The absorption, distribution, metabolism and excretion (ADME) studies using radiolabeled TAK-357 revealed that the total radioactivity was highly distributed to the adipose tissues and sustained with high concentration for over 4 weeks after oral administration. The metabolite analysis also revealed that the main component in the plasma and adipose tissues was unchanged TAK-357. The major elimination route of absorbed TAK-357 was suggested to be by metabolism. An ADME study indicated that the adipose tissue is the main depot of remaining TAK-357 in the body and slow release from the adipose tissues contributes to the long t_1/2. The PK of highly lipophilic compounds have a tendency to be affected by body weight changes especially changes in the adipose tissues. Therefore, it is considered that the relationship between the plasma levels of TAK-357 and the body weight should be evaluated carefully during the clinical trials.

Key words

pharmacokinetics - ADME - adipose tissue - distribution - long half-life

• References

• 1 Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9: 387-398
• 2 Homma A, Takeda M, Imai Y et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord. 2000; 11: 299-313
• 3 Kurz A, Grimmer T. Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease. Expert Opin Pharmacother 2014; 15: 1955-1960
• 4 Thies W, Bleiler L. 2013; Alzheimer’s disease facts and figures. Alzheimers Dement 2013; 9: 208-245
• 5 Wakabayashi T, Tokunaga N, Tokumaru K et al. Discovery of benzofuran derivatives that collaborate with insulin-like growth factor 1 (IGF-1) to promote neuroprotection. J Med Chem 2016; 59: 5109-5114
• 6 Roffey SJ, Obach RS, Gedge JI et al. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007; 39: 17-43
• 7 Levitt DG. Quantitative relationship between the octanol/water partition coefficient and the diffusion limitation of the exchange between adipose and blood. BMC Clin Pharmacol 2010; 10: 1
• 8 Jansson R, Bredberg U, Ashton M. Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 2008; 97: 2324-2339
• 9 DeJongh J, Verhaar HJ, Hermens JL. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 1997; 72: 17-25
• 10 Brown RP, Delp MD, Lindstedt SL et al. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-484
• 11 Zanghi BM, Cupp CJ, Pan Y et al. Noninvasive measurements of body composition and body water via quantitative magnetic resonance, deuterium water, and dual-energy X-ray absorptiometry in awake and sedated dogs. Am J Vet Res 2013; 74: 733-743
• 12 Muhlebach S, Bickel MH. Pharmacokinetics in rats of 2,4,5,2',4',5'-hexachlorobiphenyl, an unmetabolizable lipophilic model compound. Xenobiotica 1981; 11: 249-257
• 13 Wyss PA, Muhlebach S, Bickel MH. Pharmacokinetics of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. I. Effects of restricting food intake two weeks after administration of 6-CB. Drug Metab Dispos 1982; 10: 657-661
• 14 Jondorf WR, Wyss PA, Muhlebach S et al. Disposition of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. II. Effects of restricting food intake before and after 6-CB administration. Drug Metab Dispos 1983; 11: 597-601
• 15 Wyss PA, Muhlebach S, Bickel MH. Long-term pharmacokinetics of 2,2',4,4',5,5'-hexachlorobiphenyl (6-CB) in rats with constant adipose tissue mass. Drug Metab Dispos 1986; 14: 361-365
• 16 Geyer HJ, Scheunert I, Rapp K et al. The relevance of fat content in toxicity of lipophilic chemicals to terrestrial animals with special reference to dieldrin and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Ecotoxicol Environ Saf 1993; 26: 45-60